These findings establish the ASK1 axis as a pivotal mediator of oxidative damage in follicular atresia and identify selonsertib as a potential therapeutic agent for ovarian dysfunction associated with oxidative stress. The gene discussed is MAP3K5; the disease is ovarian dysfunction.